Navigation Links
Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent
Date:4/26/2010

quarter of 2009, started to bear fruit this quarter, and we delivered solid, 12.2 percent revenue growth and adjusted EBITDA margin improvement to 22.4 percent, year over year.

"We are very pleased with this performance," de Nicolas continued. "It demonstrates our resiliency to volatile economic conditions as well as the strength of our business model and leadership in the affordable entry-level segment -- the right place to be, in Mexico's homebuilding industry. In Q1, this is particularly reflected in our market share gain with INFONAVIT, where we moved from 4.7 percent of homes collected as of year-end 2009 to 5.4 percent this quarter.

"As we continue to work to improve our efficiency, at the beginning of this year we consolidated our affordable-entry level and middle income operations into one new division -- Homex Mexico. These unified operations will allow us to better manage projects and customer service, while enjoying economies of scale, leveraging operational efficiency across all our developments. I am confident that this consolidation will provide us more flexibility and enable us to sustain market share gains in the most profitable segments of our target markets. We also continue to work hard to improve our working capital cycle, and our first quarter results also reflect our strong relationships with suppliers, who have been offering us better credit terms and, in some cases, more competitive pricing.

"Today, we are encouraged, as we see some indicators pointing to economic recovery. We have seen continued strength in the Mexican housing market and support from the Mexican government. We are very pleased with the initial, successful replication of our business model in Brazil, as well as the growing Homex brand recognition. We are most prepared to seize the opportunities ah
'/>"/>

SOURCE Desarrolladora Homex, S.A.B. de C.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders
2. ESAs ice mission delivers first data
3. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
4. New Sony PC Delivers High Performance in Ultra-Portable Package
5. Software developed by Boston College lab delivers speed and accuracy to genome research
6. Insecticide combo delivers knockout punch
7. e-Smart(R) Technologies Delivers Its New Super Smart Card(TM) in South Korea.
8. DOE JGI Community Sequencing Program delivers first moss genome
9. Lupus Research Institute strategy delivers $30 million in national funding
10. Mountain pine beetle: Canadas new government delivers
11. Solid-state illuminator reduces nitrates in leafy green vegetables
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... recognized the outstanding work of five young researchers from ... The IOF Young Investigator Awards, valued at 1,000 USD ... submitted to the 4th Asia-Pacific Osteoporosis Meeting by researchers ... today at the Hong Kong Convention and Exhibition Centre, ...
... study by investigators from Tokyo University has found that ... sarcopenia and effective in maintaining muscle strength and physical ... process, resulting in loss of skeletal muscle mass and ... adverse health outcomes include physical disability, poor quality of ...
... BETHESDA, MD December 13, 2013 The Genetics Society ... eleven early career researchers five graduate students and six ... Nasser Award for Professional Development in Genetics. The award is ... national or international meeting, conference or laboratory course that will ...
Cached Biology News:Young investigators awarded for research excellence at Hong Kong meeting 2Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award 2Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award 3Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award 4
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" ... Special Meeting of Shareholders held today, its shareholders, including those ... Han, voted to approve the merger of Datong Investment Inc. ... Agreement and Plan of Merger dated March 26, 2010 ...
... ,, CAMPINA and PRAHOVA, Romania ... ( http://www.beikebiotech.com/index.php ), one of the,world,s leading biotechnology companies ... rehabilitation center to use traditional Chinese-style,rehabilitation techniques in Campina today. ... ...
... Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of ... of coronary and peripheral vascular disease, today announced that it will report ... fiscal 2010 on Friday, July 30 . , ... The company will hold a conference call to ...
Cached Biology Technology:Dragon Pharma shareholders approve merger and seek termination of listing on the OTCBB and TSX 2Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania 2Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania 3Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania 4Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2